Provided by Tiger Fintech (Singapore) Pte. Ltd.

Biogen

118.89
+2.402.06%
Post-market: 119.901.01+0.85%19:56 EDT
Volume:1.08M
Turnover:127.69M
Market Cap:17.40B
PE:10.63
High:119.72
Open:118.12
Low:117.40
Close:116.49
Loading ...

Ema Says Chmp: Concluded That Its Opinion Recommending Marketing Authorisation for Leqembi (Lecanemab) Does Not Need to Be Updated

THOMSON REUTERS
·
28 Feb

Indivior Parts Ways With CEO as Leadership Shakeup Continues

Dow Jones
·
27 Feb

Biogen Inc. Stock Underperforms Wednesday When Compared To Competitors

Dow Jones
·
27 Feb

Biogen Inc. Stock Outperforms Competitors On Strong Trading Day

Dow Jones
·
26 Feb

Biogen Inc. (BIIB): Among the Stocks That Will Go to The Moon According to Analysts

Insider Monkey
·
26 Feb

Pfizer Hires Top FDA Official Just Weeks After She Leaves Agency -- Barrons.com

Dow Jones
·
25 Feb

NHS England's Transition From Biogen's Drug To Sandoz's Biosimilar Sparks Alarm As Multiple Sclerosis Patients Report Severe Effects

Benzinga
·
25 Feb

Biogen Inc. (BIIB): Among the Cheap Pharmaceutical Stocks to Buy According to Analysts

Insider Monkey
·
23 Feb

Biogen Inc. Stock Outperforms Competitors On Strong Trading Day

Dow Jones
·
22 Feb

We Think Biogen's (NASDAQ:BIIB) Healthy Earnings Might Be Conservative

Simply Wall St.
·
19 Feb

Stoke Therapeutics Partners with Biogen for Zorevunersen

TIPRANKS
·
19 Feb

Strategic Collaboration Between Stoke Therapeutics and Biogen Fuels Buy Rating for Zorevunersen Development

TIPRANKS
·
19 Feb

Biogen Strengthens Pipeline With Stoke Therapeutic's Dravet Syndrome Candidate Via Multi-Million Dollar Deal

Benzinga
·
19 Feb

Strategic Collaboration with Biogen Boosts Stoke Therapeutics’ Financial and Market Position

TIPRANKS
·
19 Feb

BRIEF-Biogen And Stoke Therapeutics Enter Into Collaboration

Reuters
·
18 Feb

Stoke Therapeutics Shares up 3.5% After Co Enters Partnership With Biogen to Develop, Sell Epilepsy Drug

THOMSON REUTERS
·
18 Feb

Biogen Shares up About 1%

THOMSON REUTERS
·
18 Feb

Piper Sandler Adjusts Price Target on Biogen to $135 From $138, Keeps Neutral Rating

MT Newswires Live
·
18 Feb

Biogen Price Target Cut to $135.00/Share From $138.00 by Piper Sandler

Dow Jones
·
18 Feb

Biogen, Stoke Therapeutics Set Dravet Syndrome Collaboration

Dow Jones
·
18 Feb